Grant of Options – Replacement
This replaces the ‘Grant of Options’ announcement released on 13 September 2016 at 14:48 under RNS No 7265J. The number of options granted was corrected to 36,469.
All other details remain unchanged.
The full amended version is shown below.
|Director||No. of options granted||Percentage of issued share capital|
|Keith Neilson (CEO)||36,469||0.14|
The above options have been granted at an exercise price of 1177.5p per share (being the closing market price on 12 September 2016). These options will be subject to performance criteria, such that they vest in three equal tranches over three years. One third of the share options will vest on or after 30 June 2017, one third on or after 30 June 2018 and the final third on or after 30 June 2019. The share options will not become exercisable until three years from the date of the grant.
PDMR notification – Keith Neilson
|1. Details of the Restricted Person / person closely associated with him or her|
|a) Name||Keith Neilson|
|2. Reason for the notification|
|b) Initial notification / Amendment||Initial notification|
|3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|a) Name||Craneware plc|
|4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a) Description of the financial instrument, type of instrument||Ordinary shares of 1p each in the capital of Craneware plc|
|b) Identification code||ISIN GB00B2425G68|
|c) Nature of the transaction||Grant of options|
|d) Price(s) and volume(s)||Volume(s) granted 36,469, Price(s) n/a|
|e) Aggregated information:|
|i. Aggregated volume||Aggregate volume granted 36,469|
|ii. price||Price(s) n/a|
|f) Date of the transaction||2016-09-12|
|g) Place of the transaction||London Stock Exchange, (XLON); AIM|
For further information, please contact:
- +44 (0)20 7418 8900
- Dan Webster
- Adrian Trimmings
- George Sellar
- +44 (0)208 004 4218
- Caroline Forde
- Hilary Buchanan
- Robyn McConnachie
Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.
Craneware is the leader in automated value cycle solutions that help US provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston and Phoenix employing over 200 staff. Craneware’s market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.
You might also like...
Dec 21, 2018 | Announcements
Strong performance expected to deliver revenue and adjusted EBITDA growth in the range of 15% to 20% 21 December 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, notes the recent...read more
Nov 9, 2018 | Announcements
09 November 2018 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its final dividend announced on 4 September 2018. For those shareholders...read more